Advanced in Appendix Cancer

Pierre Dube

Montreal, QC, CA 
Advanced in Appendix Cancer
Montreal, QC, CA 
OverviewLocationsClinical Research

Overview

Pierre Dube practices in Montreal, Canada. Mr. Dube is rated as an Advanced expert by MediFind in the treatment of Appendix Cancer. His top areas of expertise are Appendix Cancer, Pseudomyxoma Peritonei, Colorectal Cancer, Colonoscopy, and Ileostomy.

His clinical research consists of co-authoring 67 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 9 articles in the study of Appendix Cancer.

Gender
Male

Locations

Montreal, QC, Canada
Other Locations
5415 Boulevard L'Assomption, Montréal, Québec, H1T2M4, Canada
Ottawa, ON K1A0R6, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
Enrollment Status: Terminated
Publish Date: July 30, 2021
Intervention Type: Drug
Study Drugs: Tesetaxel and Capecitabine, Capecitabine
Study Phase: Phase 3

67 Total Publications

ASO Visual Abstract: Radiologic and Pathologic Response as Predictors of Survival in Patients with Colorectal Peritoneal Metastases Undergoing Neoadjuvant Chemotherapy Followed by CRS-HIPEC: A Retrospective Study.
ASO Visual Abstract: Radiologic and Pathologic Response as Predictors of Survival in Patients with Colorectal Peritoneal Metastases Undergoing Neoadjuvant Chemotherapy Followed by CRS-HIPEC: A Retrospective Study.
Journal: Annals of surgical oncology
Published: November 07, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Dube's expertise for a condition
ConditionClose
      View All 11 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile